Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 9/20 | 0.47 |
| ▸ | EDNRA | P25101 | 7/20 | 0.47 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTGIR | P43119 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6858358 | 0.92 | SSTR5 (0.48) | EDNRBEDNRASSTR5KCNH2MAPT | |
| Hydrochloric Acid SCHEMBL6857505 | 0.82 | SSTR5 (0.51) | EDNRBEDNRASSTR5KCNH2MAPT | |
| SCHEMBL6856151 | 0.77 | SERPINE1 (0.50) | EDNRBEDNRASERPINE1 | |
| SCHEMBL6858380 | 0.77 | MAPT (0.53) | EDNRBEDNRASSTR5MAPTTP53 | |
| SCHEMBL27597871 | 0.77 | SERPINE1 (0.49) | EDNRBEDNRASERPINE1 | |
| SCHEMBL6856131 | 0.76 | EDNRB (0.54) | EDNRBEDNRASSTR5KCNH2TP53 | |
| SCHEMBL6859398 | 0.75 | MAPT (0.53) | SSTR5KCNH2MAPTTP53SERPINE1 | |
| SCHEMBL6859404 | 0.75 | MAPT (0.54) | EDNRBEDNRASSTR5MAPTTP53 | |
| SCHEMBL6851377 | 0.74 | EDNRB (0.49) | EDNRBEDNRASERPINE1 | |
| SCHEMBL6855135 | 0.73 | MAPT (0.63) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787651-B2 | 2-CARBOXY-SUBSTITUTED; TREATING OSTEOPENIA, OSTEOPOROSIS, CANCER, DIABETES AND ATHEROSCLEROSIS. | SMITHKLINE BEECHAM CORPORATION | 2004-09-07 | — | — | US | disclosed |
| CN-1505613-A | Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents | ʷ��˿�������ȳ�ķ����˾ | 2004-06-16 | — | — | CN | disclosed |
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | SMITHKLINE BEECHAM CORPORATION | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087902-A1 | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-gamma binding agents | PPARG, PPARA, PPARD | EDNRB 170/4885EDNRA 98/4885SSTR5 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.